What do we know is partly validatable!UEEC’s FDA-Approved Hemostatic Distributor and Clinical Study Plan
United Health Products (OTCQB: UEEC) has confirmed that the FDA has approved its proposal to collaborate with another U.S. manufacturer and distributor of hemostatic products to sponsor a new clinical study of its CelluSTAT Hemostatic Gauze biotechreporter.
Under this arrangement, the partner distributor will serve as the Sponsor of the study, while UEEC will retain exclusive rights to reference all study data for use in a revised Premarket Approval (PMA) application biotechreporter.news. The study will proceed subject to the FDA granting an Investigational Device Exemption (IDE) FT.com.
This move comes after the FDA issued a Warning Letter in March 2025 over violations from UEEC’s 2019 clinical trial. The company has been working for 14 months to address these concerns, and the FDA has also approved a Good Clinical Practices (GCP) audit by an external firm to assess UEEC’s compliance with FDA regulations biotechreporter.news+1.
CEO Bran Thom noted that the milestone “is the result of the past 14 months of investigation and discussion with the FDA” and that UEEC is in discussions with several established medical device companies for a formal collaboration agreement FT.com.
Key points:
FDA-approved partner: U.S. manufacturer/distributor of hemostatic products (name not disclosed in the announcement).
Product under study: CelluSTAT Hemostatic Gauze (neutralized regenerated cellulose, all-natural, for mild–moderate bleeding control).
Study role: Partner as Sponsor; UEEC as data holder for PMA.
Regulatory path: IDE study to demonstrate safety and effectiveness, with corrective actions and GCP audit to resolve Warning Letter.
In summary, yes — UEEC has selected an FDA-approved hemostatic distributor to conduct the clinical research, with the goal of regaining FDA approval for its CelluSTAT gauze
United Health Products (OTCQB: UEEC) has confirmed that the FDA has approved its proposal to collaborate with another U.S. manufacturer and distributor of hemostatic products to sponsor a new clinical study of its CelluSTAT Hemostatic Gauze biotechreporter.
Under this arrangement, the partner distributor will serve as the Sponsor of the study, while UEEC will retain exclusive rights to reference all study data for use in a revised Premarket Approval (PMA) application biotechreporter.news. The study will proceed subject to the FDA granting an Investigational Device Exemption (IDE) FT.com.
This move comes after the FDA issued a Warning Letter in March 2025 over violations from UEEC’s 2019 clinical trial. The company has been working for 14 months to address these concerns, and the FDA has also approved a Good Clinical Practices (GCP) audit by an external firm to assess UEEC’s compliance with FDA regulations biotechreporter.news+1.
CEO Bran Thom noted that the milestone “is the result of the past 14 months of investigation and discussion with the FDA” and that UEEC is in discussions with several established medical device companies for a formal collaboration agreement FT.com.
Key points:
FDA-approved partner: U.S. manufacturer/distributor of hemostatic products (name not disclosed in the announcement).
Product under study: CelluSTAT Hemostatic Gauze (neutralized regenerated cellulose, all-natural, for mild–moderate bleeding control).
Study role: Partner as Sponsor; UEEC as data holder for PMA.
Regulatory path: IDE study to demonstrate safety and effectiveness, with corrective actions and GCP audit to resolve Warning Letter.
In summary, yes — UEEC has selected an FDA-approved hemostatic distributor to conduct the clinical research, with the goal of regaining FDA approval for its CelluSTAT gauze
